SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
– Independent Data Monitoring Committee recommends stopping Phase 3 COMET-ICE trial early given an 85% reduction in hospitalization or death – – Vir and.
Vir Biotechnology and GSK Announce VIR-7831 Reduces Hospitalization and Risk of Death in Early Treatment of Adults with COVID-19
March 10, 2021 20:22 ET | Source: Vir Biotechnology, Inc. Vir Biotechnology, Inc. San Francisco, California, UNITED STATES
– Independent Data Monitoring Committee recommends stopping Phase 3 COMET-ICE trial early given an 85% reduction in hospitalization or death –
– Vir and GSK plan to immediately seek Emergency Use Authorization in the U.S. and authorizations in other countries –
– Additional new in vitro studies indicate VIR-7831 maintains activity against major circulating COVID-19 variants –
SAN FRANCISCO and LONDON, March 10, 2021 (GLOBE NEWSWIRE) Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that an Independent Data Monitoring Committee (IDMC) recommended that the Phase 3 COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial - Int
Vir, GSK: VIR-7831 Reduces Hospitalization And Risk Of Death In Early Treatment Of COVID-19
LONDON (dpa-AFX) - Vir Biotechnology Inc. (VIR) and GlaxoSmithKline plc (GSK, GSK.L) said Wednesday that an Independent Data Monitoring Committee or IDMC recommended that the Phase 3 COMET-ICE trial evaluating VIR-7831 or GSK4182136 as monotherapy for the early treatment of COVID-19 in adults at high risk of hospitalization be stopped for enrollment due to evidence of profound efficacy.
The IDMC recommendation was based on an interim analysis of data from 583 patients enrolled in the COMET-ICE trial. The trial demonstrated an 85% reduction in hospitalization or death in patients receiving VIR-7831 as monotherapy compared to placebo. VIR-7831 was well tolerated.
Share:
Conference Call Scheduled for 4:30 p.m. ET today
Geron Corporation (NASDAQ:GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic myeloid malignancies, today reported financial results for the fourth quarter and year ended December 31, 2020. The Company ended fiscal year 2020 with $260 million in cash and marketable securities, which is expected to fund operations until the end of 2022. Geron s vision is to be recognized as a leader in the treatment of hematologic malignancies by changing the course of these diseases and thereby improving and extending the lives of patients, said John A. Scarlett, M.D., Chairman and Chief Executive Officer. In 2020, we made important progress toward realizing that vision through two ongoing Phase 3 clinical trials, presentation of new data and analyses providing strong evidence of imetelstat s disease-modifying potential that differentiates imetelstat from